Clinical outcomes of tivozanib monotherapy as first-line treatment for metastatic renal cell carcinoma: a multicentric UK real-world analysis
Heseltine, J. Allison, Jennifer Wong, S. Prasad, K. Oong, Z. C. Wong, H. Law, A. Charnley, N. Parikh, O. Waddell, Thomas
Heseltine, J.
Allison, Jennifer
Wong, S.
Prasad, K.
Oong, Z. C.
Wong, H.
Law, A.
Charnley, N.
Parikh, O.
Waddell, Thomas
Citations
Altmetric:
Abstract
Background: Tivozanib is a licensed as first-line treatment for metastatic renal cell carcinoma (mRCC).
Objective: To evaluate the outcomes from tivozanib in a real-world mRCC population.
Patients and methods: Patients with mRCC commencing first-line tivozanib between March 2017 and May 2019 were identified across four specialist cancer centres in the UK. Data relating to response, overall survival (OS), progression-free survival (PFS) and adverse events (AEs) were collected retrospectively with censoring on 31 December 2020.
Results: A total of 113 patients were identified: median age was 69 years; 78% had ECOG PS 0-1; 82% had clear cell histology; 66% had previous nephrectomy; International Metastatic RCC Database Consortium (IMDC) score was 22% favourable (F), 52% intermediate (I) and 26% poor (P). Twenty-six per cent were switched from another tyrosine kinase inhibitor (TKI) to tivozanib due to toxicity. Median follow-up was 26.6 months with 18% remaining on treatment at data censoring. Median PFS was 8.75 months. Median PFS by IMDC risk group was: F = 23.0 months; I = 10.0 months; P = 3.0 months, p value < 0.0001. Median OS was 25.0 months (F = not reached (NR) with 72% alive at data cut-off; I = 26.0 months; P = 7.0 months, p value < 0.0001). Seventy-seven per cent had an AE of any grade, and 13% had a grade ≥ 3 AE. Eighteen per cent of patients discontinued treatment due to toxicity. No patients who discontinued a prior TKI due to AEs stopped tivozanib due to AEs.
Conclusions: These data suggest comparable activity of tivozanib with the pivotal trial data and other TKIs in a real-world population. Its tolerability positions tivozanib as an attractive first-line option for those unsuitable for combination therapies or unable to tolerate other TKIs.
Description
Date
2023
Publisher
Collections
Keywords
Type
Article
Citation
Heseltine J, Allison J, Wong S, Prasad K, Oong ZC, Wong H, et al. Clinical Outcomes of Tivozanib Monotherapy as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Multicentric UK Real-World Analysis. Targeted oncology. 2023 Jun 7. PubMed PMID: 37285073. Epub 2023/06/07. eng.